TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07150663: A Prospective, Randomized, Parallel-Controlled Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 134 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07150663 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07150663 Rescue Dossier →